10-year survival rates of more than 90% and 85%-90%, respectively [1, 2] . EGC has become increasingly common over the past two decades and now constitutes approximately 50% of gastric cancers treated in some specialized institutions in Japan. The number of patients who require follow up after curative treatment for EGC is also increasing, which provides the drive for a focused follow-up protocol, targeting those patients who are at highest risk for recurrence.
Although recurrence of EGC is rare, with an incidence of 1.4%-2.8%, patients with lymph node metastasis (node-positive EGC) have relatively higher rates of recurrence [2] [3] [4] [5] . Lymph node metastasis is considered to be the most important risk factor in predicting recurrence in patients with EGC [2, 5, 6] . Indeed, in patients with EGC without lymph node metastasis, disease seldom recurs, with an incidence of 0.6%-0.7% [3, 4] .
In this study, we investigated the risk factors and patterns of recurrence in node-positive EGC, enabling us to provide a more intensive and tailored follow up for high-risk patients.
Patients and methods
A total of 2368 patients had curative gastrectomy for solitary EGC at the National Cancer Center Hospital, Tokyo, between 1980 and 1999. Two hundred and thirty-eight patients (10%) had lymph node metastases and comprise the population of this study. The operative notes and pathological results of these patients, recorded according to the Japanese classifi cation of gastric carcinoma (the Japanese classifi cation) [7] were studied retrospectively. Survival data were obtained from hospital records or from the city registry system. Macroscopically, the tumors were classifi ed as either of depressed (type IIc, IIc+III) or elevated type (I, IIa). Histologically, they were classifi ed as either
Introduction
The defi nition of early gastric cancer (EGC) is related to depth of tumor invasion, in which the malignant cells are limited to the gastric mucosa or submucosa, regardless of lymph node metastasis. The outcome of patients with EGC after curative surgery is excellent, with 5-and differentiated type (well-or moderately differentiated adenocarcinoma) or undifferentiated type (poorly differentiated adenocarcinoma or signet ring cell carcinoma). The resected stomach and lymph nodes were histologically examined on 5-mm stepwise sections of the primary lesion and bisected planes for lymph nodes.
Univariate and multivariate analyses for risk factors of recurrence were performed using logistic regression analysis. Statistical analysis was performed with SPSS for Windows version 13.0 (SPSS, Chicago, IL, USA). The 5% signifi cance level (P < 0.05) was considered statistically signifi cant.
Results
The median age of the 238 patients with node-positive EGC was 58 years, with a male-to-female ratio of approximately 2 : 1 ( Table 1 ). Most cancers were of a depressed type macroscopically and demonstrated submucosal invasion. The proportion of differentiated and undifferentiated tumors was approximately even. One hundred and seventy-three patients (73%) were classifi ed as pN1 according to the Japanese classifi cation, which means that the tumor had metastasized only to the fi rst tier of lymph node stations. Two hundred and twenty-fi ve patients (94%) were classifi ed as pN1 (number of metastatic nodes ranged from 1 to 6) according to the International Union Against Cancer (UICC) TNM system.
The most common surgical procedure was distal gastrectomy, followed by total gastrectomy ( Table 2) . Removal of station 10, 12, or 14 lymph nodes was omitted depending on tumor location in 42 patients (18%) and all other patients underwent D2 or more extended lymphadenectomy.
Nineteen patients (8.0%) developed recurrence and the site of fi rst recurrence is detailed in Table 3 . The most common site of recurrence was lymph node (37%), followed by liver (21%). The lymph node recurrence was found in paraaortic and Virchow's nodes. Possible lymphatic recurrences (such as lymph node, lymphangiopathy, and peritoneum) were found more frequently than the hematogenous type (liver and lung). The metastatic pattern was not associated with histological subtypes. The interval between surgery and detection of recurrence ranged from 3 to 98 months, with a median of 26 months. Four patients (21%) developed recurrence 5 years after surgery. Univariate analysis revealed that increasing age, larger number of metastatic nodes, and presence of vascular invasion were signifi cant risk factors for recurrence (Table 4 ). Multivariate analysis demonstrated that the only independent risk factor for recurrence was the number of metastatic nodes ( Table 5 ). The incidence of recurrence in patients with seven or more metastatic nodes, classifi ed as pN2 and pN3 according to the UICC TNM system, was very high, reaching 38%.
Discussion
Recurrence in patients with EGC has been reported as being rare, but patients with node-positive EGC have relatively higher rates of recurrence. While the incidence of recurrence in patients with EGC has been reported as 1.4%-2.8% [2] [3] [4] [5] , in patients with nodepositive EGC it has been reported to be as high as 7%-20% [3] [4] [5] . In the present series, recurrence was found in 8.0% of the patients with node-positive EGC. This is consistent with other studies, by Lee et al. [3] (7%) and Sano et al. [4] (7.2%), in which all patients underwent D2 lymphadenectomy. D2 lymphadenectomy had been thought to contribute to lower rates of recurrences in EGC with lymph node metastasis [8, 9] . However, recent reports have raised questions about performing routine D2 lymphadenectomy for EGC. Yoshikawa et al. [10] reported that involvement of the second tier of lymph nodes (pN2 according to the Japanese classifi cation) was rare, and that D2 lymphadenectomy for EGC should be limited because of its doubtful impact on survival. In the present series, 2.7% of all patients with EGC (n = 2368) had pN2 metastasis, and this is consistent with rates of 2%-2.5% reported by other authors [10, 11] . Although D2 lymphadenectomy has been carried out safely with low mortality (0.8% [12] at Japanese high-volume centers), Western studies have shown higher morbidity and mortality rates after this procedure [13, 14] . The Japanese Gastric Cancer Association Guidelines for gastric cancer treatment [15] recommend D2 lymphadenectomy in selected patients with node-positive EGC when tumor size is greater than 2.1 cm in diameter.
The most frequent route of recurrence after curative surgery for EGC has previously been reported as hematogenous. Sano et al. [4] reported that 59% of recurrences were hematogenous type. Yoshikawa et al. [10] also reported that hematogenous metastasis was the major mode of recurrence (56.3% of recurrences). In the present study, however, possible lymphatic recurrences were found more frequently than hematogenous recurrences. The reason for this difference is that the population of the present study consisted of patients with node-positive EGC. Tumors with lymph node metastasis are thought to have lymph-oriented characteristics, leading to lymphatic recurrence.
The lymphatic and hematogenous recurrence of EGC could be explained by the infi ltration of lymphatic and vascular channels by malignant cells in the mucosal and submucosal layers. Peritoneal recurrence, most commonly seen in advanced disease with serosal invasion (pT3), has also been reported in EGC. Lee et al. [3] reported two cases of EGC with peritoneal recurrence and revealed that both of them had either lymph node metastasis or submucosal invasion. These features were also found in the two patients with peritoneal recurrence in the present study. Lee et al. suggest that invasion of lymphatics by cancer cells may form the mechanism for peritoneal recurrence in EGC.
It has been reported that the number of metastatic nodes has a prognostic signifi cance in EGC [6] . The present study has confi rmed that the number of metastatic nodes is an independent risk factor for recurrence. Recent reports have shown that patients with three or more metastatic nodes have a higher probability of recurrence and a poorer prognosis [3, 6, 16, 17] . In the present study, according to the UICC TNM classifi cation, the incidence of recurrence was 6% in patients with pN1 (≤6 metastatic nodes) and 38% in patients with pN2 and pN3 (≥7 metastatic nodes).
These fi ndings suggest that patients with a large number of metastatic nodes are at high risk of recurrence and may benefi t from adjuvant therapy as well as intensive follow up. Adjuvant chemotherapy had been thought to be ineffective for gastric cancer until recent randomized control trials (RCTs) reported positive results. The National Surgical Adjuvant Study of Gastric Cancer (NSAS-GC) study compared the survival of patients with T2N1-2 gastric cancer treated by gastrectomy alone or gastrectomy followed by oral uraciltegafur [18] . Overall and relapse-free survival rates were signifi cantly higher in the chemotherapy group (5-year overall survival, 86% vs 73%, 5-year relapsefree survival, 85% vs 68%). The Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC) study reported the effi cacy of adjuvant S-1 for stage II and III disease in 2007 [19] . Patients treated with adjuvant S-1 demonstrated a signifi cantly better 3-year survival than those who underwent surgery alone (80.5% vs 70.1%). In Japan, adjuvant S-1 therapy has become the standard treatment for stage II and III gastric cancer after curative D2 gastrectomy. Patients with node-positive EGC were not included in the ACTS-GC [19] and NSAS-GC [18] RCTs. This was partly due to the excellent prognosis after curative surgery alone and to the lack of efficacy of adjuvant therapy for EGC demonstrated by previous studies [20, 21] . The S-1 study [19] revealed that treatment was most effective in patients with stage II rather than stage III disease and the treatment was more effective in reducing lymphatic and peritoneal rather than hematogenous recurrence. These fi ndings support a possible role for adjuvant chemotherapy in patients with EGC with a large number of metastatic nodes.
In conclusion, the present study demonstrates that in patients with node-positive EGC, a large number of metastatic nodes is an independent risk factor for developing recurrence. Such recurrence is usually lymphatic and these selected patients may benefi t by having adjuvant chemotherapy.
